Inclusion Criteria:

1. Hyperinsulinemia in the upper quartile of the non-diabetic population defined as >=
10 mU/mL (based on Framingham Data, oral communication, James Meigs, MD) or fasting
glucose 110-126 mg/dL

2. Plus two of the following:

- Abdominal obesity defined by waist hip ratio > 0.90 for men and > 0.85 for women
and BMI > 30 kg/m2

- Dyslipidemia including serum triglycerides >= 150 mg/dl or serum high density
lipoprotein (HDL) < 0.9 mmol/L for men (35 mg/dL) and < 1.0 mmol/L (39mg/dL) for
women

- Hypertension defined as blood pressure >= 140/90 or on medication

Exclusion Criteria:

1. Age < 18 or > 60 years

2. Body mass index (BMI) < 30 kg/m2

3. Positive tuberculosis (purified protein derivative [PPD]) skin test (5mm induration
or more) on screening

4. Mycobacterial disease treated less than 6 months.

5. Current or recurrent infection or any underlying condition that may predispose to
infection or anyone who has been admitted to the hospital due to bacteremia,
pneumonia or any other serious infection.

6. Therapy with glucocorticoid or immunosuppressant at time of recruitment or within
past 3 months.

7. Prior or concurrent cyclophosphamide therapy

8. Use of a live vaccine 90 days prior to, or during this study.

9. History of blood dyscrasia including any kind of anemia, thrombocytopenia,
pancytopenia. Women with a reversible cause of anemia that has resolved will be
eligible.

10. Hemoglobin < 11 g/dl

11. History of malignancy (except patients with surgically cured basal cell or squamous
cell skin cancers who will be eligible)

12. History of organ transplantation

13. HIV-positive status determined by HIV test at screening or known history of any other
immuno-suppressing disease.

14. Hepatitis B or hepatitis C infection detected at screening, lupus (SLE), history of
multiple sclerosis, transverse myelitis, optic neuritis or epilepsy

15. Patients with known autoimmune or inflammatory conditions (excluding patients with
stable, treated hypothyroidism)

16. Severe comorbidities (diabetes mellitus requiring insulin, congestive heart failure
(CHF) (EF<50% at baseline will be exclusionary) of any severity, myocardial
infarction (MI), cerebral vascular accident (CVA) or transient ischemic attack (TIA)
within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe
pulmonary disease

17. Uncontrolled systolic blood pressure > 150 mmHg or diastolic blood pressure > 100
mmHg

18. Fasting blood glucose > 126 mg/dL

19. Creatinine > 1.5

20. Current use of insulin, any oral anti-hyperglycemic agents (including insulin
sensitizing agents). Initiation of insulin, oral hypoglycemics, or insulin
sensitizing agents during the study will result in discontinuation from the study.

21. Initiation of statins, niacin, antihypertensive or fibrate therapy within 6 weeks of
the study. Chronic use of fibrates, niacin, or antihypertensives for > 6 weeks prior
to study initiation at a stable dose is not exclusionary, but chronic use of statins
for > 6 months is exclusionary. Initiation of statins, fibrates, niacin or
antihypertensive treatments during the study is not exclusionary but will be
considered in the analysis (see Protection against risks).

22. Positive pregnancy test or lactating females

23. Women of child-bearing potential not currently using non-hormonal birth control
methods including barrier methods (intrauterine device [IUD], condoms, diaphragms) or
abstinence

24. Subject is currently enrolled in another investigational device or drug trial(s), or
subject has received other investigational agent(s) within 28 days of baseline visit.

25. Subjects who have known hypersensitivity to Enbrel or any of its components or who is
known to have antibodies to etanercept

26. Concurrent sulfasalazine therapy

27. History of recent alcohol or substance abuse (< 1 year)

28. Any condition judged by the patient's physician to cause this clinical trial to be
detrimental to the patient.

29. History of non-compliance with other therapies